Fox Run Management, L.L.C. Biocryst Pharmaceuticals Inc Transaction History

Fox Run Management, L.L.C.

$553 Million
Q2 2025

A detailed history of Fox Run Management, L.L.C. transactions in Biocryst Pharmaceuticals Inc stock. As of the latest transaction made, Fox Run Management, L.L.C. holds 17,725 shares of BCRX stock, worth $122,834. This represents 0.03% of its overall portfolio holdings.

Number of Shares

17,725

Previous 29,425 39.76%

Holding current value

$122,834

Previous $220,000 28.18%

% of portfolio

0.03%

Previous 0.04%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 06, 2025	SELL	$6.41 - $11.19 $74,997 - $130,923	-11,700 Reduced 39.76%	17,725 $158,000
Q1 2025 May 13, 2025	SELL	$7.06 - $9.39 $272,621 - $362,594	-38,615 Reduced 56.75%	29,425 $220,000
Q4 2024 Feb 11, 2025	BUY	$7.03 - $8.43 $192,664 - $231,032	27,406 Added 67.45%	68,040 $511,000
Q3 2024 Nov 12, 2024	BUY	$6.41 - $8.69 $28,986 - $39,296	4,522 Added 12.52%	40,634 $308,000
Q2 2024 Aug 13, 2024	BUY	$4.13 - $6.79 $72,663 - $119,463	17,594 Added 95.01%	36,112 $223,000
Q1 2024 May 13, 2024	SELL	$4.89 - $7.65 $2,557 - $4,000	-523 Reduced 2.75%	18,518 $94,000
Q4 2023 Feb 13, 2024	SELL	$4.98 - $6.77 $32,046 - $43,564	-6,435 Reduced 25.26%	19,041 $114,000
Q3 2023 Nov 07, 2023	BUY	$6.71 - $7.92 $170,943 - $201,769	25,476 New	25,476 $180,000
Q3 2022 Nov 07, 2022	BUY	$10.79 - $14.81 $53,831 - $73,887	4,989 Added 33.56%	19,854 $250,000
Q2 2022 Aug 12, 2022	BUY	$7.89 - $17.88 $117,284 - $265,786	14,865 New	14,865 $157,000
Q4 2017 Jan 18, 2018	SELL	$4.16 - $5.33 $97,344 - $124,722	-23,400 Closed	0 $0
Q3 2017 Oct 23, 2017	BUY	$4.1 - $5.97 $95,939 - $139,698	23,400	23,400 $123,000

Others Institutions Holding BCRX

# of Institutions

313

Shares Held

201M

Call Options Held

930K

Put Options Held

553K

View Full List

About BIOCRYST PHARMACEUTICALS INC

Ticker BCRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,944,992
Market Cap $1.29B
Description
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...

More about BCRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Fox Run Management, L.L.C., based on Form 13F filings with the SEC.

News

Stay updated on Fox Run Management, L.L.C. with notifications on news.

Account

Fox Run Management, L.L.C. Biocryst Pharmaceuticals Inc Transaction History